Who Paid My Doc
AMG 420 Ph1 Non-Randomized Open-Label Expansion MM
Research payments
$1,323,840
Through program year 2024, $1,323,840 in research payments was reported against AMG 420 Ph1 Non-Randomized Open-Label Expansion MM, across 38 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $54,426 | 1 |
| 2023 | Research | $14,515 | 1 |
| 2022 | Research | $97,390 | 4 |
| 2021 | Research | $617,093 | 8 |
| 2020 | Research | $540,417 | 24 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Tulio Rodriguez Maywood, IL Named on 13 payments
- Cesar Rodriguez Valdes Winston-Salem, NC Named on 7 payments
- Andrew Yee Boston, MA Named on 4 payments
- Alexander Lesokhin New York, NY Named on 3 payments
- David Hurd Winston-Salem, NC Named on 2 payments
- Luciano Costa Birmingham, AL Named on 1 payment
- Ravi Vij Saint Louis, MO Named on 1 payment
- Rebecca Silbermann Portland, OR Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.